Core Insights - ReShape Lifesciences has received a Notice of Allowance for a patent on a novel Diabetes Neuromodulation system, which aims to improve glycemic control and reduce medication dependence for Type 2 diabetes patients [1][2] - The patent will provide protection until April 12, 2039, and is part of a broader intellectual property portfolio that includes 62 issued or pending patents [2] - The Diabetes Neuromodulation technology utilizes proprietary vagus nerve block (vBloc™) technology to regulate blood glucose levels by modulating the vagus nerve's influence on the liver and pancreas [2][3] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band systems and Obalon balloon technology [4] - The company is transitioning its assets, including the DBSN™ system, to Biorad Medisys, which will own the system following the asset purchase agreement [5] Technology and Research - The Diabetes Neuromodulation system is a minimally invasive implant that delivers bio-electronic neuromodulation to regulate plasma glucose levels [3] - Pre-clinical studies have demonstrated improved glycemic control in animal models of Type 2 diabetes, indicating the potential effectiveness of the technology [2]
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology